Compare Msci Inc (MSCI) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Msci Inc vs Novo Nordisk A/S — how do they compare? Msci Inc trades at $565.12 (market cap $40.38B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 4.1× Msci Inc's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Msci Inc for 82 Days and Novo Nordisk A/S for 116 Days on average.
| MSCI | NVO | |
|---|---|---|
Market Cap | $40.38B | $165.31B |
Volume | 414,140 | 11,432,838 |
Sector | Financials | Health |
52-Week High | $643.83 | $63.98 |
52-Week Low | $511.84 | $35.29 |
Typical Hold Time | 82 Days | 116 Days |
Enterprise Value | $46.54B | $179.56B |
Dividend Yield | 1.48% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSCI trades at $561.67, up 1.13% in 24 hours, with a bullish technical signal and strong fundamental performance. The stock has exceeded earnings expectations in recent quarters, with Q3 2026 results pending. Revenue growth is steady, supported by high profit margins and recurring subscription income. Recent news highlights the completion of the First Street acquisition and upcoming earnings call, reinforcing positive business momentum.
The outlook for MSCI remains favorable, driven by robust earnings, analyst consensus of a buy rating, and a price target implying significant upside. Key risks include high valuation multiples and market sensitivity to financial services demand. Investors should weigh strong profitability against potential volatility from economic cycles.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with a P/E of 9.66, net margin of 35.35%, and consistent earnings beats. Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal expansion. Cash flow remains positive at $10.81B despite increased capital expenditures.
The outlook remains positive with 59% analyst buy ratings and a $44.67 price target representing 17% upside. Key risks include FDA delays for hemophilia drug denecimig and intensifying competition from Eli Lilly. Revenue growth continues at 6.6% annually with improving profitability margins supporting valuation expansion potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
